Mena Shehata
Pulmonary Disease · Ashland, KYNPI 1609227255
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 74.3% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $7,362, more than ten times the $270 reported in 2022.
Across 133 payments — averaging $83.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- GSK$1K
- Grifols USA, LLC$429
- Pulmonx Corporation$246
- Actelion Pharmaceuticals US, Inc.$150
- Regeneron Healthcare Solutions, Inc.$136
- plus $744 from 15 others
What the payments were for
- Travel & lodging$2,26320%
- Food & beverage$3,34030%
- Education$5,50050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $8,249 |
| GSK | 60 | $1,149 |
| Grifols USA, LLC | 13 | $429 |
| Pulmonx Corporation | 6 | $246 |
| Actelion Pharmaceuticals US, Inc. | 1 | $150 |
| Regeneron Healthcare Solutions, Inc. | 2 | $136 |
| Novartis | 6 | $121 |
| Sanofi | 3 | $90 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| AstraZeneca | 4 | $65 |
| Merck | 1 | $64 |
| ERBE USA Inc | 1 | $50 |
| Mylan Specialty L.p. | 2 | $47 |
| Viatris Specialty LLC | 2 | $45 |
| Amgen | 2 | $45 |
| Boehringer Ingelheim | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Baxter Healthcare | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,963
- UPTRAVI$150
- OPSUMIT$150
- NUCALA$125
- Prolastin-C Liquid$125
- DUPIXENT$115
How this compares
$11,103 in reported general payments places this provider in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $143,533 |
| Fasenra PenBenralizumab | 11 | $61,854 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $58,468 |
| NucalaMepolizumab | 13 | $48,284 |
| Dupixent PenDupilumab | 11 | $39,802 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $38,193 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $24,179 |
| Spiriva RespimatTiotropium Bromide | 19 | $16,464 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,397 |
| Pirfenidone | 12 | $12,000 |
| Spiriva HandihalerTiotropium Bromide | 16 | $8,670 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,275 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,152 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $3,638 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $38 | $184,17672 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,149 | $137,576160 claims |
| AstraZenecaBreztri Aerosphere | $65 | $38,19344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Ashland
- Sana GhalibAshland$16K
- Sabrina RobertsAshland$15K
- Scott NelsonAshland$12K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.